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Abstract
Inaccurate subjective seizure counting poses treatment and diagnostic challenges and 
thus suboptimal quality in epilepsy management. The limitations of existing hospital- 
and home-based monitoring solutions are motivating the development of minimally 
invasive, subscalp, implantable electroencephalography (EEG) systems with accom-
panying cloud-based software. This new generation of ultra–long-term brain moni-
toring systems is setting expectations for a sea change in the field of clinical epilepsy. 
From definitive diagnoses and reliable seizure logs to treatment optimization and 
presurgical seizure foci localization, the clinical need for continuous monitoring of 
brain electrophysiological activity in epilepsy patients is evident. This paper presents 
the converging solutions developed independently by researchers and organizations 
working at the forefront of next generation EEG monitoring. The immediate value 
of these devices is discussed as well as the potential drivers and hurdles to adoption. 
Additionally, this paper discusses what the expected value of ultra–long-term EEG 
data might be in the future with respect to alarms for especially focal seizures, seizure 
forecasting, and treatment personalization.
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1 |  INTRODUCTION
The average accuracy of seizure diaries is <50%, and this 
complicates diagnosis and management of epilepsy.1,2 
Recent progress in the development of wearable electroen-
cephalography (EEG)3–6 and non-EEG seizure detection de-
vices was reviewed in a number of papers,3,7–10 all revealing 
the unmet need for devices that could chronically monitor 
epileptic brain activity. Implantable subscalp EEG devices 
meet this need by detecting electrographic seizures, which 
has been shown to be a robust objective measure that corre-
lates to clinical symptoms.11,12 In cardiology, the invention of 
Holter electrocardiography (ECG) and the implantable loop 
recorder provided a solution for the problem of monitoring 
rare cardiac events.13,14 We anticipate a similar advance in 
neurology with respect to long-term monitoring of brain ac-
tivity in epilepsy.
Currently, scalp EEG has several critical limitations 
for long-term monitoring. Electrodes must be held fixed 
to the skin either with a cap or an adhesive, such as collo-
dion, and the skin-electrode interface must be maintained 
regularly to provide good recording quality. Despite in-
tense research on dry-electrode technology, the quality 
attained so far is not sufficient to warrant broad appli-
cability. Moreover, scalp electrodes are generally accept-
able for periods of up to 1-2 weeks at most, which might 
be insufficient if seizures are infrequent, and surveys 
show that esthetic appearance is an important variable 
to determine patients' choice of a method for ambulatory 
monitoring.15
Two commercially available intracranial devices enable 
chronic EEG monitoring. The RNS System (NeuroPace) 
continuously records counts of epileptic events per hour bin 
and provides neurostimulation. However, only snippets of 
raw data can be extracted, amounting to several minutes per 
24  hours of monitoring. Percept PC (Medtronic) provides 
neurostimulation treatment for symptoms associated with 
movement disorders and obsessive-compulsive disorder as 
well as epilepsy, where BrainSense technology can also pro-
vide a limited form of EEG monitoring (manually triggered 
30-second EEG storage and bandpass average power every 
10 minutes). However, these are invasive intracranial systems 
with a clear emphasis on therapeutic neurostimulation rather 
than diagnostics.
With this gap in mind, a handful of researchers and or-
ganizations have individually pioneered the development 
of subscalp EEG recording devices, reaching converging 
technical solutions in recent years, and are currently work-
ing on translating the invention to the clinic and market. One 
subscalp device has recently been launched in Europe (24/7 
EEG SubQ, UNEEG Medical), and more are in development 
at centers and companies around the world. In providing pre-
viously unobtainable data, these minimally invasive solutions 
may lead to a paradigm shift in the management of epilepsy, 
where clinical decisions will be based on objective brain ep-
ileptic activity, including seizure counts, sleep quality, and 
vigilance.
This review describes the novel class of subscalp EEG 
recording devices that can be implanted subcutaneously be-
tween the scalp and the cranium. A search on PubMed in 
May 2020 for (((subcutaneous OR subgaleal OR subder-
mal OR subscalp OR epicranial OR epiosteal) AND EEG) 
AND (epilepsy OR seizure)) resulted in 116 results, with 
only a few of the systems mentioned in the current article 
appearing. Given the sparse literature, we chose to perform 
a knowledge-driven review of these EEG devices. The re-
view is based on information obtained from literature, con-
ferences, and personal correspondence as well as manually 
reviewing references to articles mentioned in the literature 
of the non-EEG and wearable EEG seizure detection de-
vices mentioned above.
We describe and provide an overview of current efforts for 
subscalp EEG systems, commercially available or in devel-
opment, and discuss the utility of ultra–long-term monitoring 
using subscalp devices in epilepsy and the advantages that 
objective seizure counts can provide. We also speculate on 
K E Y W O R D S
automatic seizure detection, chronotherapy, circadian rhythm, epilepsy monitoring and recording, 
subcutaneous EEG
Key Points
• A new generation of subscalp, continuous brain 
monitoring systems have the potential to advance 
treatment and diagnosis in epilepsy
• First studies comparing subscalp recordings with 
scalp EEG are favorable and show that seizures 
can be documented electrographically
• Adoption of subscalp, ultra–long-term EEG moni-
toring may cause a shift from subjective seizure 
reporting to objective seizure counting
• The true value of ultra–long-term EEG has yet to 
be proven; more data collected over long periods 
of time are essential to show the benefit
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future possibilities of mechanistic insights into the epileptic 
brain, seizure forecasting, and combination with non-EEG 
modalities, and finally, we discuss current challenges and 
limitations of the subscalp technology.
2 |  SUBSCALP EEG AS A NEW 
MODALITY
EEG is the most important paraclinical modality in diagnos-
ing epilepsy. In addition, it helps classify seizure types and 
epilepsy syndromes.16 When routine outpatient EEG provides 
insufficient information, long-term monitoring in a hospital-
based epilepsy monitoring unit (EMU) is the next classical 
option. To mitigate the high costs of such inpatient investiga-
tions, many home-based solutions have been proposed, often 
involving a few days of scalp EEG and a webcam placed in 
the patient's house.17,18 Depending on the results of these in-
vestigations, surgical resection of the seizure focus may be 
an option, and an additional intracranial EEG study is often 
required.19
2.1 | Motivation for subscalp EEG
The development of subscalp EEG devices is motivated by 
an unmet clinical need that neither scalp nor intracranial EEG 
addresses: ultra–long-term (ie, >1 month) EEG data collec-
tion in a home environment that can reveal temporal fluctua-
tions in patterns of seizures. This may have many advantages 
for personalized epilepsy management in the context of rare 
seizures, cycles of epileptic brain activity in a majority of pa-
tients, and alternating seizure localization in some individu-
als with multifocal epilepsies (eg, bitemporal epilepsy).20–24 
Before discussing its potential for clinical practice in detail in 
Section 3, a technical review of current solutions for subscalp 
EEG follows.
2.2 | Key technical aspects
Technically, the electrodes are implanted subcutaneously 
under the scalp but above the bone. Electrode location dif-
fers among devices and can be varied for some. The subscalp 
placement removes the need for electrode care, avoids skin 
abrasions, and secures a stable and low-impedance recording, 
where several types of artifacts are attenuated.25–27 Modeling 
studies show that subscalp electrodes provide more specific 
and accurate measurements compared to scalp electrodes 
but with lower spatial and temporal resolution than intracra-
nial electrodes.28 A comparison between subscalp and scalp 
electrodes shows that the signal quality of the subscalp elec-
trodes were at least equally good during background activity 
with closed and open eyes, and might be better during bodily 
movements.29 Sleep recordings are also improved because 
subscalp electrodes are less obtrusive than scalp electrodes 
in the recumbent (sleeping) position. Many algorithms have 
been proposed to remove noise from EEG30; however, espe-
cially for the modalities with only a few channels, this will be 
challenging although not entirely impossible.31
Besides the implant, an external unit for power, data 
storage, and transmission is needed. Five of six solutions 
have opted for transmission of the data out of the implant 
(see below). This requires an external battery that is simple 
to recharge, easy to use, discreet, and unobtrusive. The sys-
tem should be able to function for prolonged monitoring for 
>30  days and potentially for many months or years. Such 
devices should also be connected to a secure, cloud-based 
database supported by software applications to help organize 
and analyze the recorded data. The same five solutions that 
opted for external battery also provide continuous raw EEG 
signals for later expert interpretation aided by detection al-
gorithms. Some solutions also include embedded software 
for real-time EEG analysis, and some solutions are aiming 
to enhance classification accuracy with multimodal detection 
algorithms by including other physiological modalities such 
as ECG, accelerometry, or voice recordings. Table 1 gives an 
overview of the different current subscalp EEG systems that 
are described below.
2.3 | Overview of current subscalp 
EEG systems
Different subscalp devices are proposed, and they vary with 
respect to the number of channels (from two to 32), degree 
of invasiveness (one incision under local anesthesia or up to 
four incisions under local or general anesthesia), and main 
application (seizure counting, alarming, forecasting, locali-
zation, neurofeedback, or neurostimulation). This section 
provides an overview of the characteristics of different sub-
scalp EEG devices that are presented below in alphabetical 
order. Figure 1 gives an overview of several of the systems 
described below as well as main application areas.
24/7 EEG SubQ from UNEEG Medical (Lynge, Denmark) 
features two bipolar channels introduced under local anes-
thesia. The SubQ was used to record EEG in healthy sub-
jects29 as well as to detect clinically relevant electrographic 
seizures in epilepsy patients, showing high reliability and 
tolerance.32,33 The device comes with dedicated software for 
automatic seizure detection and EEG visualization. The de-
vice is CE-marked, and multiple clinical trials are ongoing.34
The Epicranial Application of Stimulation Electrodes 
for Epilepsy from Precisis (Heidelberg, Germany) uses five 
subscalp platelet electrodes (four smaller electrodes arranged 
around a larger center one). This arrangement is inspired 
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by the surface Laplacian concept for improved stimulation 
depth. It is meant to be implanted above a lesioned brain area 
and/or epileptogenic focus and is capable of recording as well 
as delivering neurostimulation at an individualized closed-
loop setting.35 A clinical trial is ongoing.
The Epios system from the Wyss Center for Bio and 
Neuroengineering (Geneva, Switzerland) aims to offer flex-
ible configurations, from focal or bitemporal electrode lay-
outs to broad coverage transposing the locations of the full 
10-20 scalp EEG montage to the subscalp compartment. 
Implantation of the full montage is done under general an-
esthesia in <1 hour, through two to four small incisions 
(<1  cm) using specialized epiosteal tunneling tools. With 
lower coverage, implantation under mild sedation or nerve 
blocking is being considered. EEG data are transferred wire-
lessly to a headpiece and on to a body-worn unit for power 
and temporary storage.36 The body-worn unit also supports 
multimodal coregistration (ECG, audio, accelerometry) that 
is then transmitted to a secure cloud-based application de-
veloped to support long-term data visualization and analysis. 
Preclinical trials are currently ongoing with the Epios im-
plant, and a clinical trial is expected to start in 2020.
Minder from Epi-Minder (Melbourne, Australia) is a 
subscalp device that implants a multichannel electrode lead 
across the skull using a tunneling procedure so that both 
hemispheres are covered. Minder has the potential to provide 
long-term and continuous measures of the EEG, which will 
provide a platform to support improved diagnosis and man-
agement of epilepsy. A clinical trial is ongoing.
The Neuroview Technology Ally (Englewood, NJ) is 
being developed as a fully implantable, subscalp EEG record-
ing system to quantify seizures and aid in the diagnosis of 
infrequent paroxysmal episodes of altered consciousness or 
convulsive activity.37 The fully implanted device can record 
for 1 year of continuous use without the need to recharge. 
Low-power, on-board algorithms identify epochs of subscalp 
EEG activity suspicious for seizures and patient-identified 
events. EEG epochs are transferred to a cloud platform via a 
connected smartphone-based application for the neurologist 
to review with the aid of cloud-based machine learning al-
gorithms to verify seizures and display and quantify seizure 
activity between clinic visits. On-device detection algorithms 
can subsequently be customized to improve the specificity of 
seizure detection. Clinical trials are expected to commence 
in 2020.
UltimateEEG from BrainCare Oy (Tampere, Finland) 
uses platinum on silicon electrodes, with custom order sizes, 
number of channels, and distance between electrodes. With 
support for up to eight channels, the device offers mapping of 
seizure propagation. The planar electrodes are directionally 
focused toward the electrical sources to reduce electromyo-
graphic (EMG) noise. A clinical trial is expected to com-
mence in 2020.
2.4 | Other subscalp EEG systems
Several studies have helped clarify other aspects of subscalp 
EEG recordings, but none of these seems to have evolved 
into a commercial concept. Jochum et al38 experimented with 
an implanted EEG system on a sheep and found a correlation 
coefficient of 0.86-0.92 with simultaneous scalp EEG at the 
same location. Ahmed et al39 investigated high-density sub-
dermal EEG probes subjected to artificial aging, compared 
volume conduction simulations based on four-layered head 
models, and found that recordings from the subdermal elec-
trodes were less attenuated at higher frequencies than scalp 
EEG recordings. Do Valle et al40 investigated an eight-chan-
nel implanted EEG-recorder with electrode arrays projecting 
F I G U R E  1  Overview of different implantable parts of subscalp 
devices as well as application areas. From lower left and up: 24/7 
EEG SubQ from UNEEG medical, Denmark; the Epios system 
from the Wyss Center for Bio and Neuroengineering, Switzerland; 
UltimateEEG from BrainCare Oy, Finland; Minder from Epi-Minder, 
Australia
1810 |   DUUN-HENRIKSEN Et al.
cranially in a fanlike pattern from behind the ear and used it 
to test a seizure detection algorithm. Xu et al41 did a proof-
of-concept of subscalp EEG sensors that were comparatively 
insensitive to motion-related artifacts that can be expected to 
occur more often in daily life. In an intensive care unit set-
ting, low-maintenance subdermal wire electrodes have been 
used, but although they are quick to set up, they can also be 
dislodged easily, thus require additional fixation, and do not 
appear to be practical for chronic monitoring in daily life.27
2.5 | Other modalities
Multimodal monitoring, combining measurements of two or 
more different modalities, can be used to improve classifi-
cation accuracy above what can be achieved by using one 
modality.10,42 Heart rate variability features are correlated 
with para- and sympathetic activity, and this can be used 
to detect focal seizures or added to EEG-based detection to 
improve accuracy.42 Electrodermal activity exhibits changes 
during generalized tonic-clonic seizures (GTCS) and focal 
seizures43 and is positively correlated with longer duration 
of postictal EEG suppression.44 Audio recording could be 
useful to detect the initial vocalization or noise sometimes 
occurring during a seizure (ictal cries) or noise that can be 
characteristic of the postictal period.
Home video combined with ambulatory EEG has demon-
strated clinical utility, aiding in interpretation in 14 of 17 (82%) 
cases in one study.17 Subscalp EEG recordings could be com-
bined with video or other modalities in a similar way. Video 
quality in a home setting can be at the same level as in-hos-
pital video recordings, and a majority of patients would pre-
fer home monitoring. Cognitive and behavioral testing during 
seizures matter for seizure classification and could possibly be 
implemented in the home setting if online seizure detection al-
gorithms are sufficiently accurate, with low latency of detection 
after onset. Standardized ictal test batteries have been proposed 
and are feasible for all but very short seizures.45
2.6 | Tolerance and safety
A review of the literature on complication rates with similar 
devices for deep brain neurostimulation and occipital nerve 
stimulation revealed that expected complications include in-
fections (<2%), lead migration (~20%), fracture (~4%), and 
skin erosion (~4%).46–49 Infections, a dreaded complication 
with intracranial material, would here be limited to the sub-
scalp compartment, as the skull would act as an additional 
protective barrier for the brain. Subscalp hematoma and scalp 
fibrosis are expected to be very rare.
Prospective tolerance and safety data specific to sub-
scalp EEG come from a single trial.33 No serious adverse 
device-related events occurred, and the patients generally 
found the device easy to use, although this was only collected 
anecdotally. Minor annoyances were reported, such as diffi-
culty with simultaneously wearing glasses, occasional nightly 
disconnections, and the necessity of wearing clothes at night 
to fix the external device. No participants felt constrained in 
their ability to perform jobs or leisure activities, although six 
of nine reported mild headache up to 1 week after surgery. 
One participant reported uncommon mild headaches that 
were tolerated without analgesics or other interventions.
In a study with a subdermal wire electrode partially im-
planted for 60 days in the intensive care unit, no safety con-
cerns were noted.50
3 |  UTILITY OF SUBSCALP EEG 
RECORDING
It is estimated that 50% of seizures are unreported, par-
ticularly nocturnal seizures or focal seizures with impaired 
awareness.2 The direct consequence is the inability to ascer-
tain therapeutic response; how often is epilepsy undertreated 
when seizures are underreported, and are true changes in 
seizure frequency overlooked? Patients may also misclassify 
nonepileptic events as seizures in their diaries, potentially 
causing overtreatment. Furthermore, the issue of comorbid 
epileptic seizures and nonepileptic seizures is not uncom-
mon.51 In this section, we outline the most important aspects 
and discuss the practical utility of subscalp EEG.
3.1 | The value of personal long data
Today, there is an ongoing debate on the importance of detect-
ing purely EEG seizures that patients are unaware of and do 
not feel negatively affected by.52 This discussion is important 
for subscalp EEG, as its ambulatory nature makes simultaneous 
video unviable and thus difficult to classify seizures as clinical 
or not. Neuroimaging studies in patients with temporal lobe ep-
ilepsy have identified widespread anatomical abnormalities,53 
and longitudinal studies in patients with chronic epilepsy show 
declines in memory and intelligence quotient,54 so it is possible 
that repeated seizures have negative consequences, or perhaps 
these results come from preferential sampling of the most se-
verely affected patients with chronic refractory epilepsy. In ei-
ther case, ultra–long-term monitoring technology will be useful 
in clarifying this important question.
3.2 | The challenge of personal long data
With limited resources available for data review, a prereq-
uisite for ultra–long-term EEG systems is algorithms for 
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analysis of the vast amount of recorded data. A trained EEG 
technician can analyze 24  hours of two-channel EEG in 
2-3 hours. Use of trending tools alone can reduce the time 
for analysis by a factor of 8-10. Whether the algorithms need 
to be online or offline, simple or complex, and patient-spe-
cific or generic will very much depend on the application. 
The actual time series will always be valuable to validate 
the findings of the algorithms such that algorithms might be 
considered a data reduction method, while the final valida-
tion is still made by expert EEG reviewers supported by the 
algorithms. The right level of sensitivity must minimize the 
number of false negatives, because going through a tractable 
number of false-positive clips is highly feasible in daily clini-
cal routine. In addition to underlying algorithms, data visu-
alization is also an important issue; if a patient has worn the 
system for 6 months, a way to obtain an overview of the sei-
zure frequency, seizure duration, periodicity, and time of day 
would be crucial. With machine learning and big data analy-
sis, the prospects for automated detections are considerable.
3.3 | Objective seizure counting
Treatment decisions are informed by seizure counts, and 
there have long been calls for more reliable measures than 
what seizure diaries provide.1,2,55,56 Although wearables for 
the detection of tonic-clonic seizures in particular are gaining 
approval, the ability to automatically detect focal seizures, 
particularly with impaired awareness or without major motor 
features, remains unmet.57 Objective seizure counts may in-
form clinical decisions to avoid that an effective treatment 
is abandoned because no discernible effect in self-reported 
measures was apparent58 or that an inefficacious treatment 
is maintained or initiated on the basis of nonepileptic events, 
because nonseizure events (eg, antiepileptic drug [AED] side 
effects, nonepileptic seizures) are incorrectly classified as 
seizures by the patient.
Ultra–long-term EEG data have identified periodic pat-
terns in seizure and spike occurrences operating on different 
timescales.22 Importantly, cycles appear to be stable within 
individuals and thus potentially constitute interesting targets 
for therapeutic intervention.22,59
3.4 | Initial epilepsy diagnosis
The differential diagnosis of epilepsy is broad; syncope and 
nonepileptic seizures are commonly misdiagnosed as epi-
lepsy, and less commonly, hypoglycemia, paroxysmal disor-
ders of movement, sleep disorders, transient ischemic attack, 
migraines with aura, and transitory global amnesia.51 On top 
of that, there is also the risk of not being diagnosed with epi-
lepsy when recurring seizures are present but not identified. 
Before establishing a definitive diagnosis of epilepsy, char-
acterization of the events is a key step. Inpatient video-EEG 
monitoring is regularly successful but may not capture events 
if they are too infrequent. Figure 2 visualizes the cumulative 
probability functions for seizure detection as a function of 
monitoring duration assuming a constant seizure frequency 
where each day can be conceived as a Bernoulli trial for a 
seizure occurring. Many patients will have seizure frequen-
cies < 1/wk and are thus unlikely to have a seizure during a 
standard EMU visit.
3.5 | Seizure localization
When seizures are refractory to medical treatment, surgery is 
often indicated and has been increasingly used with improv-
ing results in the past decades.60 Presurgical workup regularly 
requires the implantation of intracranial electrodes to refine 
the localization of the seizure onset zone, sometimes in brain 
areas inaccessible to scalp or subscalp EEG. However, sub-
scalp EEG that includes bilateral electrode coverage would 
F I G U R E  2  Cumulative probability functions for seizure detection as a function of monitoring duration
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enable lateralization of seizures. A study of outpatient after 
inpatient intracranial EEG monitoring in 82 patients with me-
sial temporal lobe epilepsy of unknown laterality reclassified 
16 (20%) as having unilateral or bilateral onset, which can 
help evaluate candidates for epilepsy surgery.23,24
Subscalp EEG that offers broad head electrode coverage 
could localize to a given cerebral lobe, although studies will 
be needed to confirm this. Basing surgical decisions on doz-
ens to hundreds of electrographic seizures instead of a hand-
ful typically collected in hospital is a promising possibility 
for the future. Subscalp EEG will improve the continuum 
between optimization of medical treatment and presurgical 
planning, and represents a bridge partially mitigating both the 
critical lack of information in outpatient epileptology and the 
somewhat artificial conditions imposed in the EMU.11
3.6 | Seizure alarming
A majority of patients and caregivers want some form of sei-
zure monitoring, either at night only or 24/7, to feel more safe 
and less stigmatized.61 This is where subscalp EEG is most 
likely to improve the everyday life of a person with epilepsy. 
A large study on quality of life (QoL) in epilepsy describes 
problems in terms of lower self-esteem, higher levels of anx-
iety and depression, social isolation, stigmatization, risk of 
sudden unexpected death in epilepsy (SUDEP), and higher 
rate of unemployment.62 Injuries (burns, head and dental in-
juries) increase with higher seizure frequency. Feelings of 
stigmatization were common, and 48% worried about epi-
lepsy some or much of the time. Hopefully, a reliable online 
alarm can alleviate such issues.
SUDEP is a major cause of anxiety and is one of the 
primary motivations some people with epilepsy have for 
wanting a seizure alarm. Death following a seizure may be 
preceded by a critical interval, where an intervention could 
potentially save lives.63 Because GTCS are the main risk 
factor for SUDEP,63 the motivation for seizure alarming for 
SUDEP prevention may be weaker for focal non–tonic-clonic 
seizures. For a subscalp device to be relevant for SUDEP pre-
vention, it needs to provide at least equivalent performance to 
wearables, or it could be part of a multimodal system that is 
more robust. It could also be used to assess whether the risk 
of SUDEP changes over time for a certain patient by esti-
mating changes in the postictal EEG, although this has to be 
shown in a clinical trial.64–66
3.7 | Seizure forecasting
When patients are asked directly about the impact of seizure 
unpredictability, 66%-68% consider it an important or very 
important aspect.67 Developing systems that can predict the 
occurrence of a future seizure event with sufficient time to 
act would be a game changer. Instead of a binary output, 
the prediction could be expressed as elevated seizure risk, 
referred to as seizure forecasting. One successful demonstra-
tion of seizure forecasting used intracranial EEG recordings 
to provide visual feedback to patients minutes in advance 
of seizures.68 Much effort has been put into developing so-
lutions for seizure prediction combining intracranial EEG 
dataset and online competitions reaching classification ac-
curacies of 81%.69
However, as intracranial recordings are unlikely to be-
come widespread due to their invasiveness, it will be rele-
vant to test whether good forecasting performance can be 
achieved on subscalp recordings. Although no prospective 
study with good forecasting results on extracranial EEG has 
yet been carried out, the authors are aware of several ongoing 
studies that hopefully will shed new light on predictability 
when ultra–long-term recordings are available. Such systems 
should always be trained and tested on at least several months 
of labeled data to cover natural physiological variation70 and 
circadian and multidien cycles in epilepsy.22
3.8 | Using subscalp EEG in the future
Ultra–long-term monitoring can be used both before and 
after establishing a diagnosis of epilepsy. Long monitoring 
durations are necessary to detect rare paroxysmal events, as 
shown in Figure 2. Routinely used solutions of drug taper-
ing, sleep deprivation, and other provocations may in some 
cases induce events that differ from spontaneous seizures and 
cloud the interpretation. Therefore, an outpatient-based so-
lution may under these circumstances outperform the EMU. 
Currently, clinicians will estimate the underlying seizure fre-
quency before referring a patient to the EMU, but if ultra–
long-term EEG monitoring is an option, a probability plot as 
in Figure 2 could be informative when deciding the optimal 
diagnostic strategy. Furthermore, having a subscalp EEG 
implant does not prohibit an EMU stay for full video-EEG 
characterization; on the contrary, given that multidien cycles 
of seizures are highly prevalent among epilepsy patients,22 
the hospital stay could be timed to take place during a period 
of high likelihood of seizures.11
We envisage a toolkit, whereby subscalp devices for ultra–
long-term EEG monitoring can help detect focal or general-
ized seizures, and non-EEG modalities (EMG, ECG, others) 
could be “added on” to the setup depending on the specific 
circumstances. Furthermore, as a relationship between sleep 
quality/duration and seizure risk has been suggested, the abil-
ity to record objective sleep quality and seizures is critical to 
understanding whether strategies to improve sleep can help 
seizure control. One study has even shown that two-channel 
subscalp EEG is sufficient to do robust sleep staging.71,72
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4 |  READINESS FOR SUBSCALP 
DEVICES
As no published studies have dealt with the usability of sub-
scalp devices, we must look into the readiness for wearables, 
scalp EEG, and intracranial EEG.
4.1 | Neurologist readiness
In a survey of 21 neurologists,73 16 agreed that current am-
bulatory recordings are diagnostically useful over traditional 
inpatient recordings, and 18 agreed that there is a further 
need for wearable EEG devices. Although the questionnaire 
addresses standard ambulatory EEG, it does give a good indi-
cation that there is an unmet need that exceeds the 30-minute 
routine EEG and 1- to 3-week EMU stay.
Surveys of medical doctors’ views on the usefulness of 
seizure detection devices found that most considered alarms 
with major motor seizures and seizures associated with fall 
important, and 53% gave a 4 or 5 on a 0-5 scale of necessity 
for alarms for impaired awareness during focal seizure and 
absences.61
4.2 | Patient readiness
Patients have heterogeneous expectations for the seizure 
tracking device’s performance but describe desirable features 
in medication reminders, water-proof design, real-time data 
analysis, improved diagnostics, and seizure management.74 
Surveys suggest that patients would accept devices for sei-
zure registrations provided that they have only a small nega-
tive effect on daily life,75 but patients are concerned about 
appearance and visibility of sensors, so concealed sensors 
could help increase user acceptance.15 Subscalp sensors are 
concealed but may use an external device for power and/or 
data storage that can be hidden under the user's clothing. The 
majority (82%) of surveyed patients expected a seizure detec-
tion sensitivity of 90% or better.61
When asking the patients whether they would agree to 
wear a device on a daily basis, the participants saw the pos-
sible benefits for improved treatment effect and valued this 
benefit more than the possible inconvenience of wearing a 
sensor.15 Most (90%) would prefer the size of a wristwatch 
or smaller. Obviously, acceptance will vary on an individual 
basis and depend on the tradeoff between perceived benefit 
and the sum of inconveniences and potential side effects. It 
must be kept in mind that the questionnaires mentioned deal 
in hypotheticals regarding implantable devices, and what 
patients might imagine when posed such questions may not 
accurately reflect their reactions toward the real devices de-
tailed in this review. The implantable cardiac loop recorder 
is well accepted, and so it seems likely that with sufficient 
benefit for the recipient, implantable subscalp EEG devices 
will also be well accepted.
Some surveys suggest that up to 45.8% of patients think 
documentation of seizures is either an “important” or an “es-
sential” feature in a long-term seizure detection system.75 
Seizure alarming can help to reduce anxiety and assist auton-
omy; 60.6% of caregivers found that the seizure alarm gave 
them more freedom, and 30.3% believed that it gave the pa-
tients more autonomy.76
5 |  CHALLENGES AND 
LIMITATIONS OF SUBSCALP EEG 
RECORDERS
In this section, we outline proposed objectives in future tri-
als, considerations about low spatial resolution, logistical 
considerations relating to implantation, data management, 
and safety.
5.1 | Future trials
Future trials involving ultra–long-term monitoring in epi-
lepsy using subscalp EEG will be required to explore the 
value proposition of the technology. Although the first safety 
and feasibility studies have been completed, evidence of 
clinical usefulness of ultra–long-term EEG recordings is not 
available at the current stage of development, although mul-
tiple studies are in preparation or have commenced.
Development of seizure detection algorithms should fol-
low the standards for reporting diagnostic accuracy proposed 
in Beniczky and Ryvlin77 or Cohen.78 We should be moving 
from small sample sizes and repeated training on retrospec-
tive data to prospective trials with larger samples and pre-
defined thresholds for the algorithm’s detection. It should 
be clear whether the goal of the trial is seizure alarming or 
counting. Detection of interictal abnormalities should also 
adhere to published standards.4
Trials on seizure detection devices focus on reliable and 
accurate seizure counting, which rapidly raises the question 
of the clinical relevance of the many electrographic seizures 
typically recorded with ultra–long-term EEG. This is an op-
portunity to improve the quality of how seizures are defined, 
although the question is not trivial.52 More advanced trials 
aimed at optimizing medical management, increasing the 
ability to identify a change in seizure frequency, or inform-
ing epilepsy surgery will be necessary after this first step is 
achieved. Using the classical patient-reported outcomes for 
such trials (including seizure self-report) would defy the 
purpose. Other impacts could be quantified in terms of QoL 
scores, changes in level of disability, number of accidents, 
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and mortality, or simply whether the neurologist found a 
treatment improvement or was aided in reaching his thera-
peutic decisions.
Without a full understanding of the real seizure burden, 
outcomes of medication trials are often set for failure, pro-
longing patients suffering. Simulations based on self-re-
ported seizure events in the SeizureTracker database have 
investigated factors that can reduce costs of randomized 
clinical trials on AED efficacy without lowering statistical 
power, but did not attempt to incorporate seizure event uncer-
tainty directly into the model.79 Simulations could be useful 
in clarifying the impact of objective versus subjective seizure 
counts in epilepsy for randomized controlled trials on AEDs 
in advance of real data having been accumulated, which will 
take many years.
5.2 | Considerations regarding reduced 
spatial resolution
One disadvantage of most suggested subscalp devices 
except one compared to standard scalp EEG is reduced 
spatial resolution. For focal abnormalities, this can re-
sult in lower sensitivity compared to standard scalp EEG, 
but strategically selecting the location of the subscalp 
electrodes (eg, guided by abnormality seen on standard 
EEG or magnetic resonance imaging) might be useful 
to inform placement in individual cases. Spikes in the 
interictal EEG might inform implantation strategy, but 
unilateral implantation will likely miss seizures confined 
to the contralateral hemisphere, precluding a discovery 
of bilateral seizure onset in such cases. In the absence 
of interictal spikes and lateralizing semiology from the 
patient history, but where a strong suspicion of epilepsy 
is present, a bilateral implantation strategy could be 
considered. One development has shown that it is pos-
sible to place electrodes according to the 10-20 system 
in the subscalp space with minimally invasive surgery, 
although it is done under general anesthesia. Importantly, 
a major limitation of subscalp EEG as compared to in-
tracranial EEG is that it cannot monitor deep structures 
of the brain and has in that sense the same “field of view” 
as scalp EEG.
6 |  CONCLUSIONS
Subscalp EEG recording is an emergent technology. Studies 
comparing subscalp recordings with scalp EEG are favorable 
and show that seizures can be documented electrographically. 
Different devices are being developed to offer a range of 
subscalp electrode coverage, some with minimally invasive 
implantation of just a few electrodes under local anesthesia, 
others increasing coverage to the full head with general an-
esthesia. Some devices are fit for seizure counting, whereas 
others aim at localization.
The true value of ultra–long-term EEG has yet to be estab-
lished. It could give novel insights into brain function and is 
likely to open new avenues for biomarker discovery, person-
alized treatment, and population analytics, especially when 
combined with other complementary information such as 
movement and heart rate. Only when data have been collected 
over long periods of time will the true value of algorithm de-
velopment for seizure prediction in patients be apparent.
Adoption of subscalp EEG for ultra–long-term mon-
itoring in epilepsy will cause a shift away from subjective 
seizure reporting in favor of objective seizure counting, a 
long-awaited change. This could have a broad impact on the 
daily management of epilepsy and place patients at the center 
of management of the disorder.
For clinical science, the technology will also facilitate 
the collection of otherwise very rare ultra–long-term EEG 
recordings that could not only provide novel insights into ep-
ilepsy and other brain diseases but also provide high tempo-
ral resolution of physiological short- and long-term rhythms 
over time.
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